Medicare Enrolled
Dr. Bryant Sheh, MD
Medical Oncology · Stanford, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Sheh from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sheh?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sheh
Dr. Bryant Sheh is a medical oncology specialist in Stanford, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Sheh performed 48,751 Medicare services across 1,838 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sheh received a total of $336 from 9 pharmaceutical and/or device companies across 18 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sheh is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 10% volume in CA
$336 industry payments
Medicare Practice Summary
Medicare Utilization ↗48,751
Medicare services
Top 10% in CA for medical oncology
1,838
Unique beneficiaries
$23
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,708 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 10,800 | $43 | $88 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
9,150 | $0 | $3 |
| Denosumab injection (Prolia/Xgeva) | 7,680 | $18 | $45 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
3,950 | $10 | $75 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
3,700 | $34 | $104 |
| Anti-nausea injection (ondansetron/Zofran) | 2,252 | $0 | $1 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
1,970 | $26 | $268 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
1,830 | $22 | $190 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,460 | $0 | $1 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
1,019 | $6 | $18 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
505 | $115 | $364 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
436 | $142 | $716 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
432 | $1 | $8 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
381 | $14 | $107 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
334 | $6 | $202 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
312 | $67 | $356 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
263 | $16 | $110 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
232 | $29 | $154 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
232 | $2 | $17 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
163 | $21 | $106 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
147 | $168 | $489 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
142 | $69 | $360 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
119 | $30 | $156 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
113 | $74 | $247 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
111 | $38 | $281 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
103 | $13 | $74 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 102 | $128 | $792 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
101 | $146 | $554 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
97 | $29 | $118 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
78 | $77 | $318 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
75 | $36 | $164 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
73 | $59 | $309 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
69 | $1 | $2 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
63 | $20 | $98 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
57 | $34 | $291 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
51 | $2 | $15 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
45 | $108 | $365 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
37 | $1 | $14 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
28 | $24 | $74 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
27 | $27 | $131 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
12 | $177 | $821 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
23.4% high complexity
74.0% medium
2.6% routine
Industry Payment Transparency
Open Payments through 2024 ↗$336
Total received (2018-2024)
Avg $56/year across 6 years
Bottom 21% in CA for medical oncology
9
Companies
18
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$176 (52.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$160 (47.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$147
2023
$29
2022
$96
2021
$14
2020
$13
2018
$37
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$43
Janssen Biotech, Inc.
$35
Adaptive Biotechnologies Corporation
$28
E.R. Squibb & Sons, L.L.C.
$21
ARRAY BIOPHARMA INC
$20
Top 3 companies account for 71.7% of 2024 payments
All-time payments by company (2018-2024) ›
Acrotech Biopharma LLC
$78
PFIZER INC.
$75
Seattle Genetics, Inc.
$37
Janssen Biotech, Inc.
$35
Novartis Pharmaceuticals Corporation
$29
Adaptive Biotechnologies Corporation
$28
E.R. Squibb & Sons, L.L.C.
$21
ARRAY BIOPHARMA INC
$20
Merck Sharp & Dohme Corporation
$13
Top 3 companies account for 56.4% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · BELEODAQ · IBRANCE · INLYTA · LENVIMA · OPDIVO · RYBREVANT · XALKORI · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (52%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
56
Per 100K population
2.9
County median income
$159,674
Nearest hospital
STANFORD HEALTH CARE
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Sheh is a mixed practice specialist, with above-average Medicare volume (top 10% in CA), with low-engagement industry engagement, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Sheh experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Sheh performed 10,800 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sheh receive payments from pharmaceutical companies?
Yes. Dr. Sheh received a total of $336 from 9 companies across 18 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sheh's costs compare to other medical oncologists in Stanford?
Dr. Sheh's average Medicare payment per service is $23. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sheh) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Stanford
Browse medical oncologists in Stanford ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in CA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in CA
Which CA medical oncologists receive the most from drug and device companies.
By company
Acrotech Biopharma LLC Payments to Doctors
See all physicians who received payments from Acrotech Biopharma LLC.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Seattle Genetics, Inc. Payments to Doctors
See all physicians who received payments from Seattle Genetics, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology